Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. We: identify the signaling dysfunction driving a patientâs cancer that genetic tests cannot detect; directly measure the effectiveness of a targeted therapy in patientâs living tumor cells; confirm the therapeutic matching the patientâs cancer driver is present and functional in the cells before prescribing treatment, striving to improve the likelihood of a positive clinical outcome. Source
No articles found.
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Cerus Corporation is dedicated solely to safeguarding the worldâs blood supply a...
Cerus Corporation is dedicated solely to safegu...
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...
Arena Pharmaceuticals is driven to deliver nove...
Utah Medical Products IncÂŽ, established in 1978, develops, manufactures and marke...
Utah Medical Products IncÂŽ, established in 197...
We are dedicated to the discovery, development, and commercialization of novel hig...
We are dedicated to the discovery, development,...
Aeglea a clinical-stage biotechnology company that engineers next generation human...
Aeglea a clinical-stage biotechnology company t...
IDEXX Laboratories, Inc. is a member of the S&P 500ÂŽ Index and is a leader in pet...
IDEXX Laboratories, Inc. is a member of the S&P...
Quidel Corporation (Nasdaq: QDEL) is a California-based leading manufacturer of di...
Quidel Corporation (Nasdaq: QDEL) is a Californ...
Voom has developed a multi-platform wellness program to address both the injuries ...
Voom has developed a multi-platform wellness pr...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
Join the National Investor Network and get the latest information with your interests in mind.